Proyecto VALIDA: Validation of ALlergy In vitro Diagnostics Assays (Herramientas y recomendaciones para la valoración de las pruebas in vitro en el diagnóstico de la alergia)

Casas, María Luisa Maestro de las; Esteban, Ángel; González‐Muñoz, Miguel; Labrador-Horrillo, Moisés; Pascal, Mariona; Teniente‐Serra, Aina

doi:10.1515/almed-2020-0022

Cited by 3 publications

(3 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides the theory reported by Kleine-Tebbe and Jakob ( 14 ) exposing that a 0.01 or greater ratio of specific IgE to total IgE, translated as a fraction of 1% of bound total IgE, is enough for basophil half-maximal activation, we observe basophil activation with a lower percentage. Thus, reliable quantitative detection of sIgE and the ratios analysis of specific and total IgE on these patients is relevant for an accurate diagnosis ( 13 , 15 ).…”

Section: Discussionmentioning

confidence: 99%

Low Levels Matter: Clinical Relevance of Low Pru p 3 sIgE in Patients With Peach Allergy

et al. 2022

Self Cite

View full text Add to dashboard Cite

Many clinical lab settings still use 0.35 KUA/L as the cut-off for serum specific-IgE (sIgE) immunoassays, while the detection limit is 0.1 KUA/L. The clinical relevance of -low-level sIgE (0.1–0.35 KUA/L) remains controversial. Pru p 3 sIgE is considered to be the main routine tool for assessing lipid transfer protein (LTP) sensitization. We aimed to evaluate the clinical relevance of Pru p 3 sIgE low levels in a population diagnosed with LTP allergy. Adults diagnosed with LTP allergy and Pru p 3 sIgE ≥ 0.1 KUA/L between 2012 and 2019 were included. Clinical data were reviewed. nPru p 3 basophil activation test (BAT) was performed and basophil reactivity (BR) and sensitivity (BS) correlated with the peach allergy symptoms. Pru p 3 sIgE from 496 subjects was recorded, 114 (23.0%) between 0.1 and 0.34 KUA/L (grLOW), the rest ≥ 0.35 KUA/L (grB). A total of 44.7% in grLOW and 59.9% in grB were allergic. Urticaria was more frequent in grLOW. In grLOW, Pru p 3 sIgE was higher in patients with local compared with systemic symptoms. In grB, Pru p 3 sIgE was higher in allergic patients. Pru p 3/Total IgE ratios were higher in allergic vs. tolerant in both groups. In BAT, BR was similar in both groups. In grLOW, it was higher on allergic compared with tolerant (p = 0.0286), and on those having systemic vs. local symptoms (p = 0.0286). BS showed no significant difference between groups. Patients with low levels represent a non-negligible fraction and around 45% are peach allergic. BAT showed functional sIgE in them. Pru p 3 sensitizations should be carefully evaluated even when sIgE levels are low.

show abstract

Section: Discussionmentioning

confidence: 99%

Low Levels Matter: Clinical Relevance of Low Pru p 3 sIgE in Patients With Peach Allergy

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Therefore, new methods, in particular CRD, should be used to improve diagnosis of pet allergies. The World Allergy Organization (WAO), the ARIA initiative, and the Global Allergy and Asthma European Network (GA 2 LEN) provided an updated consensus document on CRD in 2020 [10], and the project VALIDA in Spain issued a number of recommendations on the best use of the different in vitro techniques for IgE determination, including CRD [21]. Of note, however, in our study, some (6.9%) patients with dog allergy were CRD negative, despite being SPT positive.…”

Section: Color Version Available Onlinementioning

confidence: 99%

Using Component-Resolved Diagnosis to Characterize the Sensitization to Specific Cat and Dog Allergens in Patients with Allergic Respiratory Diseases in Catalonia, Spain

Roger¹,

Lazo²,

Arias³

et al. 2023

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Introduction: Sensitization to cat and dog allergens is common in patients with allergic respiratory diseases. The study objective was to determine the prevalence of immunoglobulin E (IgE) sensitization to specific cat and dog allergens using component-resolved diagnosis (CRD) in patients with allergic respiratory diseases plus cat and/or dog sensitization. Methods: We included 87 patients aged 8–62 years, diagnosed with allergic asthma and/or rhinitis plus cat and/or dog sensitization, and attended at the allergy section of a tertiary hospital in Badalona (Catalonia, Spain). We used CRD to determine IgE sensitization to specific cat/dog allergens and skin prick tests (SPTs) to determine differences between diagnostic test results. Results: Patients were monosensitized to cats (20.7%) or dogs (3.4%) or sensitized to both (75.9%). The highest positive allergen rates were for Fel d 1 (91.7%) and Fel d 4 (41%) in patients sensitized to cat allergens and for Can f 5 (80%) and Can f 1 (70%) in those sensitized to dog allergens. CRD and SPT results differed somewhat: 16.1% and 27.6% of patients CRD positive for cat or dog sensitization, respectively, were SPT negative, and 6.9% SPT positive for dog sensitization were CRD negative. Few statistically significant relationships were found between any allergen components and any respiratory disease characteristic or contact with furry animals. Conclusions: CRD may be used to determine the prevalence of IgE sensitization to specific cat and dog allergens in patients with allergic respiratory diseases plus cat and/or dog sensitization. As SPT may not correctly identify all patients sensitized to cats and dogs, our results support the use of CRD.

show abstract

“…The 2 main multiplex sIgE determination platforms in use today are the microarray ImmunoCAP ISAC E112i and the macroarray ALEX2. 2 Given that the results generated are not interchangeable between the platforms, 3 it is important to clinically validate both methods.…”

Section: Introductionmentioning

confidence: 99%

Would the choice of multiplex platform impact the management of the allergic patient? A first approach focusing on LTPs

Cabrera,

Horrillo,

Brito

et al. 2023

Clinical Laboratory Analysis

View full text Add to dashboard Cite

BackgroundIn the Mediterranean area, patients with LTP syndrome who are sensitized to multiple allergens are often tested for sIgE using multiplex platforms. The results obtained from different commercial platforms are not interchangeable, so it is important to compare and validate the platform selected for use. The objective of this study is to compare and validate the performance of the ImmunoCAP ISAC E112i and the macroarray ALEX2 in our daily practice.MethodsFrom August 2021 to March 2022, we tested 20 random serum samples from polysensitized patients using the ALEX2 test (MADx) and ImmunoCAP tIgE and ISAC E112i (Thermo Fisher Scientific). We compared the total IgE (tIgE) and sIgE levels for shared allergens.ResultsThe heatmap generally showed more intense results for ISAC. The overall correlation was good, but some exceptions were noted. The main discrepancies were found for Ole e 7, which was positive for 11 patients in ISAC but negative for all patients in ALEX2, and for nut LTPs, for which ISAC showed a threefold higher detection rate for Ara h 9 and a fivefold higher detection rate for Cor a 8 and Jug r 3 compared to ALEX2. The regression model showed no interchangeability of tIgE results.ConclusionsDespite our small sample size and the complexity of comparing a quantitative and a semi‐quantitative platform, our results suggest that patient diagnosis and management can be influenced by the platform used. Therefore, our findings must be taken into consideration when choosing a platform to use for some profiles of LTP‐polysensitized patients, even though more data is needed.

show abstract

Proyecto VALIDA: Validation of ALlergy In vitro Diagnostics Assays (Herramientas y recomendaciones para la valoración de las pruebas in vitro en el diagnóstico de la alergia)

Cited by 3 publications

References 66 publications

Low Levels Matter: Clinical Relevance of Low Pru p 3 sIgE in Patients With Peach Allergy

Low Levels Matter: Clinical Relevance of Low Pru p 3 sIgE in Patients With Peach Allergy

Using Component-Resolved Diagnosis to Characterize the Sensitization to Specific Cat and Dog Allergens in Patients with Allergic Respiratory Diseases in Catalonia, Spain

Would the choice of multiplex platform impact the management of the allergic patient? A first approach focusing on LTPs

Contact Info

Product

Resources

About